Amylyx Pharmaceuticals Inc expected to post a loss of 73 cents a share - Earnings Preview

Amylyx Pharmaceuticals

06/08/2024 14:37

* Amylyx Pharmaceuticals Inc  AMLX.OQ   AMLX.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 8 for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 89.1% decrease in revenue to $10.663 million from $98.22
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Amylyx Pharmaceuticals
Inc is
for a loss of 73 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Amylyx
Pharmaceuticals Inc is $3.75​, above​ its last closing price
of $1.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   0.02        -0.01      -0.12     Missed  -1,900
 Dec. 31 0001  0.24        0.23       0.07      Missed  -69.3
 Jan. 1 0001   0.43        0.44       0.30      Missed  -31​
 Jun. 30 2023  0.08        0.10       0.31      Beat    210
 ​​Jan.        -0.23       -0.24      0.02      Beat    108.3
 1 0001                                                 
 Dec. 31 2022  -0.82       -0.82      -0.65     Beat    20.7​
 Sep. 30 2022  -0.97       -0.97      -0.92     Beat    5.3
 Jan. 1 0001   -0.88       -0.87      -0.93     Missed  -6.6
 This summary was machine generated August 6 at 13:37 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)